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Abstract:  
CDK4/6 inhibition with endocrine therapy is now a standard of care for advanced estrogen receptor 
positive breast cancer. Mechanisms of CDK4/6 inhibitor resistance have been described pre-clinically, 
with limited evidence from clinical samples. We conducted paired baseline and end of treatment 
circulating tumor DNA sequencing from 195 patients in the PALOMA-3 randomized phase III trial of 
palbociclib plus fulvestrant versus placebo plus fulvestrant. We show that clonal evolution occurs 
frequently during treatment, reflecting substantial sub-clonal complexity in breast cancer that has 
progressed after prior endocrine therapy. RB1 mutations emerged only in the palbociclib plus fulvestrant 
arm and in a minority of patients (6/127, 4.7%, p=0.041). New driver mutations emerged in PIK3CA 
(p=0.00069) and ESR1 after treatment in both arms, in particular ESR1 Y537S (p=0.0037). Evolution of 
driver gene mutations was uncommon in patients progressing early on palbociclib plus fulvestrant but 
common in patients progressing later on treatment. These findings inform future treatment strategies to 
address resistance to palbociclib plus fulvestrant. 
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Statement of significance 
Acquired mutations from fulvestrant are a major driver of resistance to fulvestrant and palbociclib 
combination therapy. ESR1 Y537S mutation promotes resistance to fulvestrant. Clonal evolution results 
in frequent acquisition of driver mutations in patients progressing late on therapy, which suggests that 
early and late progression have distinct mechanisms of resistance.  
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Introduction 
Selective cyclin dependent kinase 4 and 6 (CDK4 and CDK6) inhibitors have become the standard of 
care for advanced, estrogen receptor positive (ER+), HER2 negative metastatic breast cancer (1). 
Estrogen and oncogenic signaling increases cellular levels of the D type cyclins, particularly cyclin D1, 
activating CDK4 and CDK6 in a process modulated by the INK4A protein family, which includes p16, 
p21 and p27 (2). Activated CDK4/6 phosphorylates retinoblastoma (Rb), in turn partially activating the 
E2F transcription factors which promote S phase entry in a positive feedback loop involving cyclin E 
and CDK2 (3,4). Multiple phase III studies have now demonstrated that CDK4/6 inhibitors significantly 
prolong progression free survival in combination with endocrine therapy in ER positive breast cancer 
(5-8), identifying the CDK4/6-Rb axis as central to the biology of this subtype of breast cancer. 
With CDK4/6 inhibitors now a standard of care, it is critical to identify the mechanisms of resistance to 
therapy and develop treatment strategies after clinical progression. A number of putative resistance 
mechanisms to CDK4/6 inhibition have been identified in preclinical models: RB1 loss, cyclin E1 and 
cyclin E2 amplification (9), and CDK6 amplification (10). Clinical evidence is limited, with a case report 
of RB1 mutations in  three patients treated with CDK4/6 inhibitors (11), but no systematic assessment 
of resistance mechanisms. Mutations in RB1 are rare in primary breast cancer (12) but the prevalence 
of these in endocrine pre-treated and CDK4/6 inhibitor resistant breast cancer is unknown. Loss of 
function RB1 mutations may render the tumor resistant to subsequent endocrine-based therapies or 
prevent benefit from continuing CDK4/6 inhibitors beyond progression, so identifying how frequently 
the tumor acquires RB1 mutations is important in planning trials of post-CDK4/6 therapy. In addition, 
prior data has suggested that common genomic aberration such as PIK3CA mutations and ESR1 
mutations have limited value as a biomarker for CDK4/6 inhibitor treatment (13).  
Here we provide a comprehensive assessment of the genetic aberrations of CDK4/6 inhibitor resistant 
disease using circulating tumor DNA analysis of paired baseline and end of treatment plasma 
samples from the PALOMA-3 study. The PALOMA-3 study was the first phase III trial of a CDK4/6 
inhibitor in ER+, HER2- advanced breast cancer, randomizing both pre- and postmenopausal patients 
who had previously progressed on endocrine therapy to either palbociclib plus fulvestrant (P + F) or 
placebo plus fulvestrant (F), and demonstrating an improvement in median progression free survival 
from 4.6 to 11.2 months with the addition of palbociclib to fulvestrant (14), updated in (15). Analysis of 
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paired samples from this randomized study allows a dissection of which genetic events are acquired 
through therapy, specifically which component of the combination therapy may be driving selection of 
the mutations. Acquired mutations observed only in the palbociclib plus fulvestrant group likely 
promote resistance to the CDK4/6 inhibitor, while acquired mutations at equal frequency in both 
groups likely promote resistance to fulvestrant and, in general to endocrine therapy.  
We demonstrate that RB1 mutations arise following treatment with CDK4/6 inhibition, but that these 
mutations are likely subclonal and of relatively low prevalence, suggesting, in contrast to previous 
work, that they are not a major mechanism of resistance. Relatively frequent acquisition of new 
PIK3CA and ESR1 mutations, in particular the ESR1 Y537S mutation, in both treatment arms, 
implicate these changes in the development of parallel mechanisms of resistance to the elements of 
combination treatment and suggest new avenues for therapy.  
 
7 
 
Results 
Exome sequencing of plasma DNA reveals clonal evolution on palbociclib plus fulvestrant 
From the 521 patients who were enrolled in the PALOMA-3 study there were 459 patients with a 
baseline (day 1 of treatment) plasma sample available, 287 of these having a matched end of 
treatment (EOT) (Supplementary figure 1). The patients with paired samples from this group had 
similar palbociclib benefit compared to the overall PALOMA-3 study population (Supplementary figure 
2). Of patients without available matched end of treatment samples (n = 172), 94 had not progressed 
(94/172, 54.6%) compared to 74 in the matched set (74/287, 25.8%). We first identified paired day 1 
and EOT samples for plasma DNA exome sequencing to achieve comprehensive assessment of 
progression genetic events on palbociclib plus fulvestrant (Figure 1A). To identify paired plasma 
samples with sufficient tumor purity for exome sequencing, we developed a novel copy number and 
purity targeted sequencing strategy using a targeted amplicon panel that included approximately 1000 
single nucleotide polymorphisms (SNPs) in regions commonly lost in breast cancer  (See Materials 
and Methods, Supplementary figure 3) and combined this with digital PCR data for PIK3CA and ESR1 
mutations (13). Using this approach we identified 16 patients treated with palbociclib plus fulvestrant 
who had high tumor DNA purity in plasma (>10% tumor purity) at day 1 and EOT, with adequate 
material for exome library preparation (Supplementary table 1). Of these, 9/16 (56.3%) had a PIK3CA 
mutation and 6/16 (37.5%) an ESR1 mutation in day 1 ctDNA. Five patients had matched germline 
DNA, and a further 3 additional unmatched germline DNA samples were also sequenced to expand 
the panel of germlines for filtering sequencing noise. As only 6 patients from the fulvestrant plus 
placebo arm had matched samples meeting the quality control criteria these were not sequenced. 
Plasma DNA underwent exome sequencing to a median depth of 164X (range 139 – 212), with 
germline DNA sequenced to a median depth of 47X (range 34 – 58) (Supplementary table 2). Two 
day 1 samples had evidence of contamination and these pairs were excluded from comparative, 
paired analyses. The number of non-synonymous variants detectable in the day 1 samples varied 
considerably between patients (range 19 – 254, Supplementary figure 4). Analysis of the mutational 
signatures across all samples revealed the most prevalent were signatures 1 (age) and 3 
(homologous recombination deficiency), consistent with existing data on breast cancer (16) 
(Supplementary table 3). Day 1 exome sequencing data additionally revealed genetic markers 
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potentially relevant to the development of endocrine resistance beyond ESR1 mutations  - mutations 
in the NOTCH family receptors NOTCH2, NOTCH3 and NOTCH4  in 4/14 (28.6%) patients, and NF1 
mutations in 2/14 patients (14.3%, Supplementary table 4). Genomic instability indices were broadly 
stable between day 1 and end of treatment for most patients, although as seen with mutation burden 
there was considerable variation between patients (Supplementary figure 5). 
Clonal evolution and selection on palbociclib plus fulvestrant was clearly evident between day 1 and 
EOT plasma in 85.7% 12/14 patients (Figure 1, Supplementary figure 6). Patient 390 had two RB1 
truncating mutations, p.Q257X and p.N519fs, that were only detected at end of treatment (Figure 1B). 
Clonality analysis with PyClone (17) suggested these RB1 mutations were in a resistant subclone, or 
potentially separate subclones with parallel evolution leading to phenotypic convergence, with a 
further treatment-sensitive sub-clone evident characterized by a RUNXT1 mutation that regressed on 
treatment (Figure 1C). Mutation counts per subclone as determined by the PyClone model were 155 
(cluster 1), 64 (cluster 2) and 51 (cluster 3). The mutations in the resistant sub clones were 
predominantly consistent with the APOBEC mutation signature (Figure 1D, Supplementary table 3). 
The RB1 mutations were validated by digital PCR and confirmed to be absent at the start of treatment 
(Figure 1E).  
A second patient, 253, during treatment with palbociclib plus fulvestrant exhibited marked selection of 
a subclone featuring an activating mutation in the tyrosine kinase domain of FGFR2 p.K569E, not 
detectable in the day1 sample (Figure 1F). Mutations counts per subclone as determined by the 
PyClone model were 51 (cluster 1), 49 (cluster 2), 54 (cluster 3) and 20 (cluster 4). The newly 
dominant resistant sub clone, with an additional ESR1 mutant Q75E daughter clone, replaced the day 
1 ESR1 D538G mutant clone that was negatively selected by treatment (Figure 1G). As Q75E is not a 
recognized cause of resistance to aromatase inhibitors and is positioned outside the ligand binding 
domain of ESR1, these findings in this case suggest changes in the dominant ESR1 mutation 
between day 1 and EOT may reflect sub-clonal selection potentially unrelated to functional 
consequences of the ESR1 mutation, with different ESR1 mutations marking individual clones rather 
than potentially emergence of the resistant clone. As seen with the resistant sub clone in patient 390, 
the newly dominant FGFR2 mutant sub clone in patient 253 also had a substantial proportion of 
mutations consistent with the APOBEC signature, with the minor daughter sub clone mutations 
dominated by the mismatch repair signature (Figure 1H, Supplementary table 3). Selection of the 
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FGFR2 mutation was validated by digital PCR (Figure 1I). In three further patients there was possible 
evidence of selection of emergent mutations in antigen presentation pathways (Supplementary table 
4). 
These findings demonstrate that clonal evolution is frequent in breast cancer on palbociclib plus 
fulvestrant, with evidence that the genomic plasticity of emergent subclones can be driven by different 
mutational processes from the bulk disease that is dominant at the start of treatment. 
 
Patients acquire new driver mutations in both treatment arms 
Paired exome sequencing findings were used to develop a targeted sequencing panel for error 
corrected ctDNA sequencing of all available paired plasma samples, with DNA from each sample 
input into two separate library preparations and sequenced on two sequencing platforms with different 
fundamental chemistry, then compared together for final analysis to reduce both PCR error and 
sequencing error (see Materials and Methods).  The targeted panel included all the coding exons of 
RB1, CDK4, CDK6, CDKN1A, CDKN2B, NF1, exons 5-8 of TP53, and known mutation hotspots in 
PIK3CA, ESR1, ERBB2, FGFR1, FGFR2, FGFR3, AKT1, KRAS, NRAS and HRAS. RB1 was 
included on the basis of the pre-existing literature, with FGFR1/2/3 and NF1 added following the 
exome sequencing. In addition to the 14 patients with paired exome sequencing, libraries were 
generated from 206 patients at both day 1 and EOT for targeted sequencing (Supplementary figure 1, 
Supplementary figure 7). These underwent sequencing to median coverage of 2187X and 3251X for 
day 1 and EOT samples respectively on an Ion Proton, and to median coverage of 10637X and 
8947X  for day 1 and EOT samples on an Illumina HiSeq 2500, yielding 184 patients with paired 
sequencing data from both platforms meeting quality requirements (Materials and Methods, 
Supplementary figure 1). Combined with the paired exome sequencing this yielded 195 patients with 
paired ctDNA sequencing data (3 patients being included in both sets, Supplementary figure 1) to 
investigate selection on treatment with palbociclib plus fulvestrant (n=127) or fulvestrant and placebo 
(n=68). 
Initially considering both treatment groups together, overall there were more mutations detected at 
end of treatment than at day 1, with 183 variant calls made in 105 patients at day 1 versus 243 variant 
calls in 119 patients at end of treatment (Figure 2A). Sixty patients had at least one newly 
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detectable/acquired mutation at the end of treatment (60/195, 30.8%). The acquisition of mutations at 
end of treatment did not appear to reflect low day 1 tumor content, as there were similar proportions 
of detected day 1 mutations in both patients with and without acquired mutations (35/60, 58.3% 
versus 70/135, 51.9% respectively). Additionally there was no significant difference in the proportion 
of patients with >10% tumor purity at baseline (20.8% for patients with an acquired mutation, 31.0% 
for those without, p = 0.21, Fisher’s exact test), calculated using the SNP panel on a subset of n = 
163 day 1 samples. There were similar proportions of patients in both treatment groups who acquired 
at least one new mutation, 39/127 (30.7%) in the palbociclib plus fulvestrant arm and 21/68 (30.9%) in 
the placebo plus fulvestrant arm. 
Six patients acquired detectable RB1 mutations at end of treatment (p = 0.041, McNemar’s test with 
continuity correction), all of these patients having received palbociclib plus fulvestrant. Two of these 6 
patients had 2 RB1 aberrations, one patient having been previously identified from the exome 
sequencing, suggesting polyclonal resistant sub clones (Figure 1C, Figure 2B). The Q257X mutation 
identified in sample 418 was also validated with ddPCR (Figure 2B). In the 6 patients who acquired 
RB1 aberrations, all 8 variants were either a gain of a stop codon or a frameshift deletion, highly likely 
to result in abrogated Rb function. Four of the 6 patients who developed an RB1 mutation also 
featured a PIK3CA mutation at a much higher allele fraction, suggesting that the RB1 mutations could 
reflect sub clones (Supplementary figure 8). Considering the two orthogonal sequencing approaches, 
amplicon and exome capture, similar end of treatment RB1 mutation frequencies were identified in 
both at end of treatment in the palbociclib plus fulvestrant arm (exome sequencing  7.1%, 1/14, 
amplicon sequencing 3.9%, 5/127).  These observations support the emergence of RB1 aberrations 
being acquired or selected under pressure from palbociclib, but only in a minority of patients (6/127, 
4.7%). Although we did not identify any RB1 mutations at day 1 this is chance result, we  identified 2 
patients (in the fulvestrant plus placebo arm) RB1 mutations in a wider set of 331 day 1 samples that 
included patients without EOT samples. 
Besides the emergence of RB1 mutations on palbociclib, analysis of variants through treatment 
revealed different patterns across different genes, but a similar pattern between treatment groups 
(Figure 2C). For TP53 there was predominantly persistence/maintenance of variants present at day 1 
(Figure 2A, Figure 2C), consistent with variants in these genes commonly representing truncal 
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changes. One patient with a day 1 TP53 mutation acquired 8 newly detectable variants in TP53 at 
EOT (Supplementary figure 9). 
 
Selection of PIK3CA mutations on treatment 
For PIK3CA, considering both treatment arms, 39 variants in 37 patients (37/195, 19.0%) were 
identified in the day 1 samples (Figure 2A), consistent with previous findings (13) and indicating low 
levels of polyclonality. Almost all PIK3CA mutations present at day 1 were maintained after treatment 
(37/39, 95.7%), consistent with the majority of these being clonal/truncal mutations (Figure 2C). At 
end of treatment, 55 PIK3CA variants in 52 patients from both treatment groups (52/195, 26.7%) were 
detected, an increase compared to day 1 (Figure 2A, p = 0.00069, McNemar’s test). There was 
acquisition of PIK3CA mutations in 8.2% patients overall (16/195, one of these acquiring 2 separate 
mutations and another patient acquired an additional PIK3CA variant (Figure 2C). The acquired 
PIK3CA mutations were validated with ddPCR for H1047R, H1047L, E545K and E542K (the most 
common, accounting for 16/18 acquired variants) with 100% (16/16) of these validating and showing 
close agreement with the sequencing allele fraction estimation (r = 0.97, Supplementary figure 10). 
Considering specific PIK3CA mutations, there was some limited evidence for positive selection of 
E542K (p = 0.041, McNemar’s test with continuity correction, q = 0.41, Bonferroni correction, 
Supplementary figure 11). Using digital PCR to test day 1 samples, a minority of the acquired PIK3CA 
mutations had the ‘acquired’ mutation detectable at day 1 by digital PCR (6/18, 33.3%, 
Supplementary figure 12), with most of these at very low allele frequency below the limit of detection 
by ctDNA sequencing, providing evidence in some patients for outgrowth of a minor pre-existing 
PIK3CA mutant sub-clone. The increased proportion of PIK3CA mutant patients at the end of 
treatment remained statistically significant in an analysis that included the digital PCR data at day 1 (p 
= 0.016, McNemar’s test). The proportion of patients acquiring newly detectable PIK3CA mutations 
did not appear to differ between treatment groups (Figure 2C, Supplementary figure 13, 
Supplementary figure 14). These data are consistent with a proportion of initially PIK3CA wild type 
tumors either positively selecting very low prevalence PIK3CA mutant sub clones, or newly acquiring 
them on treatment with fulvestrant. 
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Selection of ESR1 Y537S on treatment 
ESR1 mutations were observed in patients 25.1% of patients at the start of treatment (49/195, 25.1%, 
Figure 2A), with a similar overall number of patients with an ESR1 mutation at the end of treatment 
(61/195 , 31.3%, p = 0.07 McNemar’s test). However, 6.7% (13/195) patients had an ESR1 mutation 
detected at baseline and did not have an ESR1 mutation detected at progression, and similarly 12.8% 
(25/195) patients without an ESR1 mutation detected at baseline had a newly acquired one at 
progression (Supplementary figure 14). Assessment of ESR1 mutation status at baseline by digital 
PCR showed good overall agreement with the sequencing results (Supplementary figure 15). 
Considering individual ESR1 mutations, there was strong evidence for positive selection specifically of 
ESR1 Y537S through treatment in both treatment groups (p = 0.0037, McNemar’s test, q = 0.047, 
Bonferroni correction Figure 3A). All of the acquired Y537S mutations were validated in the end of 
treatment samples by repeat testing with digital PCR (17/17, Figure 3B). Considering the samples 
with a Y537S call in either time point, there was a minority of the acquired ESR1 Y537S mutations 
that had the ‘acquired’ mutation detectable at day 1 by digital PCR (3/17, 17.6%, Figure 3C), 
providing evidence in some patients for outgrowth of a minor pre-existing ESR1 Y537S mutant sub-
clone. The increased proportion of ESR1 Y537S mutant patients at the end of treatment remained 
statistically significant in an analysis that included the digital PCR data at day 1 and end of treatment 
(p = 0.0019, McNemar’s test). An exploratory analysis of progression free survival comparing patients 
with a Y537S mutation at day 1 to those who acquired Y537S by end of treatment  showed a trend to 
significance despite the small numbers (log rank p = 0.011, Supplementary figure 16).  There were no 
clear differences in acquisition of specific ESR1 mutations between treatment arms (Supplementary 
figure 17). Taken together, these data are consistent with ESR1 Y537S promoting resistance to 
fulvestrant in the clinic.  
Variants in further genes were acquired on treatment including hot-spot activating mutations in 
ERBB2 (1.5%, 3/195), KRAS (0.5%, 1/195), FGFR2 (1.0%, 2/195), with no obvious difference in 
selection between treatment groups (Figure 2C). 
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Clonal evolution of mutations with treatment  
We next contrasted the clonal changes observed in different genes across both treatment arms, 
separately considering the course of individual clones, and of patients with different combinations of 
sub-clones (Figure 4A, Figure 4B). Genes with strong patterns of acquisition of new variants such as 
RB1 and PIK3CA tended to lose relatively few clones on treatment (Figure 4C, Figure 4D). In 
contrast, ESR1 mutations showed substantial variation through treatment, with frequent loss and gain 
of different mutations through treatment (Figure 4E, Figure 4F, Supplementary figure 14), and high 
levels of ESR1 polyclonality (13). Patients commonly had a different combination of ESR1 mutations 
detectable at EOT compared to day 1 (Figure 4F, Supplementary figure 14), and only 35.6% ESR1 
variants detected at any time point were detected at both and thus maintained on treatment (42/118). 
This pattern of polyclonal flux observed in ESR1 mutations, supports the observation that individual 
ESR1 mutations mark individual tumor sub-clones (Figure 1), demonstrating the frequent clonal 
selection pressure provided by treatment.  
 
Copy number profiles remain predominantly consistent through treatment. 
We next assessed copy number variation in plasma. Exome copy number profiles (n = 14) were 
largely consistent between day 1 and EOT on palbociclib plus fulvestrant (Supplementary figure 18, 
Supplementary figure 19), contrasting with the clonal evolution observed in single nucleotide variants 
(Figure 1). Loss of 13q, encompassing the RB1 locus, was lost in 6/14 (42.9%) patients at day 1 and 
5/16 (31%) patients at end of treatment, with the majority of these being present in the day 1 (4/5, 
80%, Supplementary figure 20). There was no change in these findings with incremental reduction in 
the bin size, to investigate for large intra-genic deletions in RB1. 
To expand copy number profile assessment beyond the exome sequencing, we assessed a larger set 
of matched pairs of day 1 and end of treatment samples from both treatment groups using the 
targeted sequencing panel that assessed loss of RB1, PTEN and CDKN2A, tumor purity and 
assessment of copy number in 12 genes commonly gained in breast cancer (Materials and Methods). 
In total, 324 samples were sequenced to assess copy number with median 1329X coverage, 
comprising 163 day 1 samples and 154 paired EOT samples (Supplementary figure 21, 
Supplementary figure 22). 
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As assessing copy-number in plasma DNA, and in particular copy number loss, is highly dependent 
on having sufficient tumor purity only the subset of samples with at least 20% tumor purity were used 
for assessment of losses. Of the day 1 samples, 37 had estimated ≥20% purity, with 51 EOT samples 
having ≥20% purity yielding 17 patients for paired analysis (Supplementary figure 23). There was an 
association between number of sites of disease and tumor content >10% (p = 0.039, Cochran-
Armitage test). Loss of RB1 was identified in 6/37 patients (16.2%) in day 1 samples and 14/51 
patients (27.4 %) with end of treatment samples (p = 0.30, Fisher’s exact test). Among these losses it 
was also possible to identify sub-genic deletions with our approach (Supplementary figure 22, 
Supplementary table 5). In EOT samples we identified 3.8% (2/51) sub-genic deletions, one of these 
also having a paired day 1 sample with the loss, suggesting these deletions pre-existed and were not 
acquired during treatment. In the 17 samples with paired >20% purity there was no evidence for 
selection of RB1 loss on treatment (Supplementary figure 24, p = 0.25, McNemar’s test), although this 
analysis was limited by sample size. Consistent copy number though treatment was also observed for 
PTEN and CDKN2A (Supplementary figure 24).  
Copy number gain data at day 1 and end of treatment was assessed in those samples with >10% 
tumor purity and were largely consistent with the spectrum seen in primary breast cancer, with 
amplifications identified in CCND1, MYC and FGFR1, without evidence for selection or loss at end of 
treatment in the 43 samples with paired purity >10% (Supplementary figure 25). Two patients 
acquired FGFR2 amplification at end of treatment (Supplementary figure 25). There were no patients 
with acquired CCNE1 or CCNE2 amplification at end of treatment.  
 
Selection of genetic variants occurs late on palbociclib plus fulvestrant 
To investigate clinical factors that associated with selection of mutations on treatment, we explored 
the relationship between time of treatment (PFS) and acquisition a new mutation at EOT (Materials 
and Methods) in both patients on palbociclib plus fulvestrant (Figure 5) and placebo plus fulvestrant 
(Supplementary figure 26). The presence of any acquired mutation at the end of treatment was 
associated with longer PFS compared to patients that did not acquire a mutation (Figure 5A, median 
14.3 months acquired vs 5.5 months not acquired, log rank p = 0.0018, Supplementary figure 27, 
Supplementary figure 28), suggesting that new mutations were more likely to arise in patients who 
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had been on treatment longer.  This trend was also seen separately for acquired ESR1 mutations 
(Supplementary figure 29, median PFS 13.7 acquired versus 7.4 months not acquired, log rank p = 
0.032) and PIK3CA mutations (Supplementary figure 30, median 12.7 acquired versus 9.2 months 
not-acquired, log rank p = 0.34), mutations in these two genes comprising the majority of the acquired 
mutations (Figure 5B). There were too few acquired RB1 mutations to meaningfully assess a 
relationship with PFS (Supplementary figure 31). Assessment of baseline clinic-pathological 
characteristics with patients who had acquired a mutation revealed some evidence of an association 
with the presence of bone metastases (p = 0.013, q = 0.15, Supplementary table 6). 
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Discussion 
CDK4/6 inhibitors in combination with endocrine therapy now represent the standard of care for 
advanced hormone-receptor positive breast cancer, but little is known about mechanisms of 
resistance to these treatments. Here we study the evolution of genetic mechanisms of resistance to 
palbociclib plus fulvestrant in these breast cancers and show that clonal evolution is frequent in 
response to therapy. Three main changes in driver genes are identified. Acquired mutations in RB1 
occur relatively infrequently, and are often sub-clonal, detected in the plasma of 5% of patients after 
palbociclib plus fulvestrant (Figure 2A-C). Acquired driver mutations in growth factor receptors and 
signal transduction pathways are frequently detected in patients treated with palbociclib plus 
fulvestrant, occurring in 39/127 (30.7%) of patients in total (Figure 2C, Figure 5D), dominated by 6% 
of these patients acquiring PIK3CA mutations, with 9% more patients having at least 1 ESR1 mutation 
by end of treatment compared to day 1 (Figure 5D). Evolution of ESR1 mutations is observed, with 
selection of ESR1 Y537S as the variant most likely promoting resistance to fulvestrant in the 
combination (Figure 3A, Figure 4E).  Conversely, as acquisition or selection of the mutations 
examined in our panel was seen predominantly in patients with longer treatment duration. This 
suggests that patients with tumors intrinsically resistant to treatment less frequently acquire 
mutations, presumably due to the lack of selective pressure of treatment, and that other mechanisms 
of resistance may dominate in early progression. 
Preclinical work has identified RB1 mutations(9,11) as a mechanism of resistance to CDK4/6 
inhibition, consistent with the literature that functional Rb is required for the efficacy of CDK4/6 
inhibitors (18). Of these potential mechanisms of resistance only mutations in RB1 have been 
identified in the clinic although their prevalence in a treated population is unknown (11). Condorelli 
and colleagues have recently reported 3 patients with RB1 mutations following treatment with CDK4/6 
inhibition, 2 of these receiving palbociclib with fulvestrant in the setting of previous endocrine 
treatment, and the other ribociclib and letrozole as first line for advanced disease (11). With the 
advantages of analyzing an unbiased registration study, our study confirms apparent positive 
selection of RB1 aberrations on palbociclib plus fulvestrant, but demonstrates they are only evident in 
a minority of patients (Figure 2A).  In these patients we identify polyclonal RB1 aberrations, 
suggestive of phenotypic convergence under selective pressure, such as is seen with ESR1 
mutations in response to endocrine therapy (13,19). Intriguingly, RB1 mutations were only selected in 
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tumors wild-type for ESR1 mutations (Figure 2D). Although we are unable to exclude a chance 
finding, this does possibly suggest that RB1 mutations could be selected when fulvestrant efficacy is 
not compromised by ESR1 mutation, suggesting divergent routes to resistance. Our findings of 
relatively uncommon RB1 mutations is important in suggesting that subsequent lines of endocrine 
based therapy have the potential to be active on progression, concurring with currently available post-
progression clinical data(15).  
With the exception of RB1 mutations, there was no evident difference in acquired mutation profiles 
between the fulvestrant and palbociclib versus fulvestrant and placebo groups (Figure 2C). This 
observation within the context of a randomized trial suggests that resistance to fulvestrant is a major 
genetic driver of resistance to combination therapy, possibly with tumors able to adapt to CDK4/6 
inhibition without ER signaling suppressed. ESR1 mutations are an important mechanism of 
resistance to aromatase inhibitors, with mutations in the ligand binding domain, particularly helix 12, 
resulting in a constitutively active protein (20,21). Nevertheless, the detection of multiple resistant sub 
clones at baseline did not predict palbociclib activity in PALOMA-3 (13). Our data suggests a 
significant proportion of ESR1 mutations present at day 1 are lost on palbociclib plus fulvestrant, at 
least in part reflecting the high level of clonal evolution on therapy with loss of ESR1 mutations 
reflecting loss of the sensitive sub clone (Figure 1C, 1G), with others emerging during subsequent 
fulvestrant treatment at the same rate and pattern in both treatment groups (Figure 2C).  We find 
evidence for positive selection of Y537S at end of treatment (Figure 3A, Figure  3D, Figure 4E), this 
being the ligand binding domain mutation identified in pre-clinical studies as the most resistant to 
fulvestrant (22). This suggests separate, parallel evolution of mechanisms of resistance to the 
combination of palbociclib plus fulvestrant.  
Further acquired driver mutations were observed in growth factor receptors and signal transduction 
pathways (Figure 5D). PIK3CA mutations are important founding variants in ER positive primary 
breast cancers (12) and remain clonally dominant in most metastatic breast cancers (23). We now 
identify that 6% of patients with no detectable PIK3CA mutations at day 1 acquire, or positively select, 
newly evident PIK3CA mutations at the end of treatment  with palbociclib plus fulvestrant (Figure 2C, 
4A, Figure 4C, Figure 4D), in particular E542K in this study (Supplementary figure 11). The 
prevalence of emergent PIK3CA mutations did not appear to differ between treatment groups 
(Supplementary figure 13), favoring the hypothesis that these are principally effecting fulvestrant 
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resistance (24). Through exome sequencing we identify a role for ABOPEC in driving clonal diversity 
and resistance to palbociclib plus fulvestrant (Figure 1D, 1H, Supplementary table 3). We note E542K 
is a potential APOBEC site, with the dominance of E542K potentially providing further evidence to 
support APOBEC mutagenesis in promoting genetic diversity in advanced ER positive breast 
cancer(25,26).  
Our study also has potentially important findings in relation to the existing pre-clinical literature on 
mechanisms of resistance to CDK4/6 inhibitors. Prior pre-clinical work identified acquired amplification 
of CCNE1(9) or CDK6(10), in palbociclib and abemaciclib resistant models respectively. We find no 
evidence that acquired CCNE1, CDK4 or CDK6 amplification are relevant in the clinic, although we do 
note that circulating tumor DNA analysis is limited in analyzing copy number due to the challenge of 
low tumor purity. We partly address this limitation by adopting a novel targeted sequencing approach 
to allow concurrent assessment of purity and copy number, restricting copy number analysis for gain 
to those tumors with at least 10% tumor purity, and loss to those with at least 20% tumor purity 
(Supplementary figures 21 -25). Our plasma tumor purity observations are comparable to the third of 
patients having >10% tumor content in the large breast cancer set reported in Adalsteinsson et al 
(27), with the slightly higher rates of observed purity in our study (42% of day 1 samples, 68/163, and 
53% of end of treatment samples, 82/154) perhaps due to be explained by all the samples being 
processed under the strict protocol mandated in the study. However, we emphasize that ctDNA 
analysis would be unlikely to detect many sub-clonal amplifications or losses. In addition, we find no 
evidence for gatekeeper mutations in CDK4 or CDK6, and can effectively exclude this from being a 
common mechanism of resistance (Figure 2A). 
Our study has a number of limitations. Making comparisons between longitudinal time points in 
circulating tumor DNA is difficult due to variations in tumor content - inability to identify mutations may 
be a result of absence of tumor DNA in plasma, or presence at a low level that falls into the 
sequencing noise. We mitigate this concern by conducting secondary analyses - analyzing baseline 
plasma with digital PCR for newly emergent mutations, and performing a subset analysis of patients 
with known day 1 tumor content. The problem of purity is particularly challenging for assessing 
genomic loss, compounded for comparative analyses where confidence is required in the tumor 
content at more than a single time point. This may limit the investigation of RB1 loss, and we suggest 
that tissue based analysis will be required for a definitive analysis of copy number on progression. 
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Although we analyzed 14 patients by paired exome sequencing, for discovery and to design our 
targeted panel, we cannot address whether there are rare acquired events not interrogated by our 
targeted panel. Additionally, we have interrogated relatively few end of treatment plasma samples 
from patients with over 2 years treatment duration, and so we are unable to address whether very late 
progression may have a different pattern of acquired mutations. Finally, we use the term ‘acquired’ in 
this manuscript to reflect a mutation detectable at EOT that was not detectable at day 1. It is very 
challenging to assess whether these mutations may have pre-existed in the tumor prior to treatment in 
a minor and undetectable subclone. Investigating this exhaustively for Y537S with very high sensitivity 
digital PCR we do detect at very low level some of the ‘acquired’ and ‘lost mutations at day 1 and end 
of treatment respectively, but show that these are balanced between the two time points and do not 
significantly affect the comparative result (Figure 3D).  
Our study has important clinical implications for future therapeutic approaches in breast cancer. 
Resistance to fulvestrant is identified as a major driver of resistance to the combination of palbociclib 
plus fulvestrant. A number of potent oral selective estrogen receptor downregulators (SERDs) are in 
clinical development, and our findings suggest that more potent targeting of the estrogen receptor has 
potential to improve on fulvestrant in combination with palbociclib. Oral SERDs should specifically 
address their clinical activity against ESR1 Y537S. A number of targetable kinase mutations are 
enriched on palbociclib plusfulvestrant, with an approximate doubling of the number of detectable hot-
spot activating ERBB2 mutations, activating FGFR mutations and high level acquired FGFR2 
amplification, all of which invite precision medicine-guided therapeutic approaches after progression. 
Mutations in PIK3CA are selected through fulvestrant therapy, suggesting a greater role for PI3 
kinase inhibitors after therapy as well as the potential for triple combination therapy (ER, CDK4/6, PI3 
kinase) to prevent the outgrowth of resistant clones driven by acquired PIK3CA mutations. 
Our work demonstrates the value of interrogating large registration trials with paired ctDNA analysis, 
demonstrating how ongoing clonal evolution in breast cancer drivers undermines palbociclib plus 
fulvestrant therapy, highlighting a potential role for APOBEC mutagenesis in promoting clonal 
evolution, and identifies rational therapeutic strategies that could improve efficacy of CDK4/6 
inhibition. 
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Materials and methods 
PALOMA-3 Study design 
The PALOMA-3 trial was a phase III, double-blind randomized controlled trial comparing palbociclib 
plus fulvestrant to placebo plus fulvestrant in patients with ER+/HER2- advanced breast cancer. The 
trial recruited 521 patients randomized in a 2:1 ratio to receive oral palbociclib 125 mg daily, 3 weeks 
on, 1 week off, or matched placebo. All patients received fulvestrant 500mg every 4 weeks. Pre-
menopausal women received goserelin in addition. Patients were eligible if they had either 
progressed on endocrine treatment for advanced disease or progressed during or within 12 months 
following adjuvant endocrine therapy.  
 
Plasma collection and processing 
Blood samples were collected at day 1 of treatment and end of treatment in EDTA blood collection 
tubes. These were centrifuged within 30 minutes at 1500-2000g before separation of the plasma and 
storage at -80C and transfer to a central laboratory. Prior to extraction plasma was centrifuged again 
at 3000g for 10 minutes and the supernatant used for extraction. DNA extraction was performed using 
the Circulating Nucleic Acid kit (Cat No./ID: 55114)  from Qiagen® (Venlo, Netherlands). DNA was 
quantified using a Taqman-based digital PCR assay against RPPH1from LifeTech® (California, USA, 
Cat no. 4403326). Buffy coat were available was extracted using the Qiagen Qiacube according to the 
manufacturer’s instructions. 
 
Digital PCR 
Digital PCR experiments were performed with Taqman probes in 20ul reactions partitioned into 
20,000 micelles in an oil and water emulsion using the Bio-Rad® AutoDG® system before undergoing 
PCR in a G Storm thermocycler. Prior to use, cycling conditions for each Taqman assay was 
optimized using a thermal gradient and G-blocks from Integrated DNA Technologies (Iowa, USA). 
Droplets were read on a Bio-Rad® QX200 and concentrations calculated by fitting a Poisson model to 
the data using Bio-Rad® QuantaSoft version 1.4.0.99. Day 1 DNA samples were screened for ESR1 
mutations S463P (c.1387T>C), Y537N (c.1609T>A) E380Q (c.1138G>C), L536R (c.1607T>G), 
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Y537C (c.1610A>G), D538G (c.1613A>G) and PIK3CA mutations E542K (c.1624 G > A), E545K 
(c.1633 G > A), H1047R (c.3140 A > G) and H1047L (c.3140 A > T) as previously described(13). For 
the purposes of exome sequencing, end of treatment samples were tested for a mutation with digital 
PCR only if a mutation was found in the matched day 1 sample to estimate purity. For purity estimates 
from digital PCR allele fractions mutations were assumed to be heterozygous with a copy number of 
2.  
 
Exome sequencing 
Matched day 1 and end of treatment samples with adequate material (minimum 13ng to preserve 
library complexity) and purity (10%) were selected for exome sequencing. Hybrid capture libraries 
were prepared using Agilent SureSelect V6 with paired end sequencing performed on an Illumina 
HiSeq 2500 to a target depth of 150X for plasma and 50X for germline. Reads were aligned to the 
hg19 reference using BWA v0.7.12 (28) and duplicates removed with Picard (v2.8.2) according to 
GATK best practices (28). Copy number was assessed using cnvkit v0.8.4 (29) and purity with 
ASCAT 2 (30). Variant calling between pairs was performed with MuTECT v1.1.7 (31), MuTECT2 
(GATK v3.7), VarDict v1.5.0 (32) and between samples and the panel of germlines using MuTect2 
and GATK. Variants were only considered if they had coverage of 40X and were identified by 2 
callers. Clonality analysis was performed with PyClone (0.13.0)(17), the mutational signature analysis 
with the R package deconstructSigs (33) and the chromosomal instability indices as described in 
Andor et al(34). For samples without matched germline DNA, PyClone was used to identify and 
screen germline SNPs from paired analysis. For samples without matched germline DNA putative 
SNPs were removed from analysis either using a variant allele fraction (VAF) cut off < 0.4 or by 
comparing VAF in both EOT and day 1 samples. Copy number profiles were compared using GISTIC 
(35). Additional diagrams and fish plots were produced using clonevol (36). Sequencing data are 
publically available at the Sequencing Read Archive, using the accession number SRP157645. 
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Targeted copy number and purity panel 
A 1729 amplicon custom panel was designed using the Ampliseq designer software (Thermo Fisher 
Scientific, Waltham, USA) to allow combined copy number and purity assessment. For purity 
assessment the panel included approximately 100 SNPs with population prevalence over 20% in 8 
chromosomal regions that commonly exhibit loss of heterozygosity in breast cancer: 16q24.3, 17p12, 
8p23.2, 11q23.3, 22q13.31, 1p36.13, 6q27, 3p21.31. Assessment of tumor purity was validated down 
to 10% by comparison with validated digital PCR assay allele fraction (Supplementary table 7). For 
robust assessment of loss a similar approach was used to include RB1, CDKN2A (p16) and PTEN 
with 119, 134, and 128 SNPs for each, respectively. For copy number assessment approximately 20 
amplicons were sited in 11 genes commonly amplified in breast cancer and 19 reference genes 
identified from TCGA(12)  and METABRIC(37) data as being relatively copy number invariant. 
Libraries were constructed with 1-3ng input using the IonTorrent Library kit v2.0 (Thermo Fisher 
Scientific, Waltham, USA) and sequenced to a target depth of 1000-2000X on the Ion Proton using P1 
chips. Reads were aligned using Torrent Suite software. Loss of heterozygosity was estimated using 
a bespoke pipeline that used a threshold of 5% for the presence of a ß allele based on variance seen 
in germline material with a minimum of 15 informative SNPs (Supplementary figure 32, 
Supplementary table 8) using an approach adopted from previous CLONET analyses (38,39). A 
minimum of 4 amplicons was used. Purity was estimated by assuming a single diploid clone with loss 
of heterozygosity, with this approach yielding similar estimates of purity to digital PCR 
(Supplementary table 7)  and CLONET(40) (Supplementary figure 33), with reported profiles in the 
validated set matching the expected distribution from the TCGA (Supplementary figure 34). Copy 
number was assessed using the OncoCNV (v6.8) (41) package with calls based on normalized logR 
values obtained using thresholds of 0.24 for gain and -0.18 for loss. These thresholds were 
established using 3 standard deviations from the mean, derived from sequenced germline samples 
using the purity panel. To account for inter-gene variability within the panel an additional z test with an 
α of 0.05 was performed against the local logR for all the samples.  Copy number estimates were 
adjusted for purity where purity exceeded the minimum threshold of 10%. Primers capturing CCNE2 
were only included for 226/324 samples, and so CCNE2 was not assessable in the other 98 samples. 
RB1 loss was defined as either evidence of heterozygous loss (normalized logR < -0.18 with or 
without evidence of LOH) or probable homozygous loss where the adjusted copy number was <1.  
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Targeted gene panel sequencing 
The AmpliSeq designer (Thermo Fisher Scientific, Waltham, USA) was used to create a 305 amplicon 
custom panel with amplicons covering the coding exons of RB1, CDK4, CDK6, CDKN1A, CDKN1B, 
NF1, exons 5 – 8 of TP53 and mutational hotspots in ERBB2, PIK3CA, AKT1, ESR1, FGFR1, FGFR2 
and FGFR3. Two libraries were constructed for each sample with 1.5 – 5ng of DNA per primer pool at 
each time point with the initial multiplex PCR of 22-24 cycles depending on input.  One set of libraries 
were taken through the conventional IonTorrent Library kit v2.0 protocol, while the matched set was 
cleaned with AMPure XP (Beckmann Coulter, Bera, USA) beads following FuPa digestion and the 
library prep completed using the KAPA Hyper Prep kit with dual-index adaptors without further PCR. 
The IonTorrent libraries were then sequenced to a target depth of 2,000X on a Proton with P1 chips. 
The custom libraries were sequenced on an Illumina HiSeq 2500 to target coverage of 15,000X. 
Sequencing reads were aligned and BAM files generated for the IonTorrent libraries using the Torrent 
Suite software and with BWA for the Illumina libraries. Sequencing artefact was removed with  
iDES(42) and manual curation with variants called from pileup only if present in both datasets above 
an allele fraction of 0.3% for hotspots, stopgains and frameshifts and 0.5% for all other calls, with a 
minimum of 5 alternative reads. VarDict was used to call indels under the same constraints on both 
platforms and torrent caller was used for IonTorrent libraries and Mutect2 for Illumina libraries. This 
approach was validated using dilutions of a blend of circulating tumor DNA (Supplementary figure 35). 
 
Statistical analyses 
Kaplan Meier survival analyses for progression free survival were performed with the log rank test 
using a Cox proportional hazards model to obtain hazard ratios and 95% confidence intervals. 
Comparison of frequency of particular genomic aberrations in unpaired day 1 samples versus end of 
treatment was done using Fisher’s exact test. Analysis of paired data between day 1 and end of 
treatment was performed using McNemar’s test with a continuity correction where required. Unless 
stated otherwise all p values were two-sided with an α of 0.05. Statistical analyses were conducted 
using R version 3.4.3. To address potential under-sampling at the day 1 time point, for the survival 
analysis comparing patients with and without an acquired mutation mutations were only included as 
acquired if the variant calls in the Ion Torrent and Illumina libraries passed an additional statistical 
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test. The proportions of alternative and reference reads between day 1 and end of treatment were 
compared using Fisher’s exact test, with only those calls with p < 0.05 in both libraries being included 
in the survival analysis. Of 60 patients with acquired mutations, 53/60 met these criteria and were 
included in the survival analysis. Survival analyses were conducted using the latest data cut off from 
the trial (October 2015) in which the median PFS was 4.6 months for fulvestrant plus placebo and 
11.2 months for palbociclib plus fulvestrant(15). 
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Figure legends 
 
Figure 1. Paired circulating tumor DNA (ctDNA) exome sequencing reveals frequent clonal 
selection on fulvestrant plus palbociclib 
A – Day 1 and end of treatment plasma samples from the PALOMA-3 trial were screened using 
droplet digital PCR and a targeted SNP sequencing approach to identify patients from the palbociclib 
plus fulvestrant arm who had paired plasma samples of sufficient tumor purity (>10%) for plasma 
exome sequencing. 
B – Paired ctDNA exome sequencing in patient 390 analyzed for clonal composition. A newly 
emergent RB1-mutant clone is detected at EOT, harboring two inactivating RB1 mutations.  
C – Inferred phylogenetic tree of breast cancer from patient 390 derived from ctDNA. Yellow - truncal 
mutations present in all cancer cells; Purple -subclone present at day 1 that subsequently regressed 
on treatment: Gray - a newly emergent resistant clone characterized by two RB1 mutations, arising 
separately to the purple sub clone. 
D – Representation of mutational signatures identified in each individual sub clone for patient 390. 
The raw data are shown in Supplementary table 3. 
E – Digital PCR validation of the two RB1 mutations Q257X and N519fs identified in the treatment-
resistant sub clone from patient 390. Results for day 1 and EOT are shown, Y axis mutant probe 
amplitude and X axis wild type probe amplitude. 
F – Paired ctDNA exome sequencing in patient 253 analyzed for clonal composition. A new FGFR2 
mutant clone undetectable at day 1 is detected at EOT.  
G – Inferred phylogenetic tree of breast cancer from patient 253 derived from ctDNA. Yellow - truncal 
mutations present in all cancer cells; Purple - subclone characterized by an ESR1 D538G mutation 
present at day 1 that subsequently regressed on treatment; Orange - newly emergent resistant clone 
characterized by an FGFR2 kinase domain mutation, arising separately from the purple sub clone; 
Gray – a sub clone arising from the FGFR2-mutant sub clone characterized by a Q75E ESR1 
mutation. 
H – Representation of mutational signatures identified in each individual clone from patient 253. The 
raw data are shown in Supplementary table 3. 
I – Digital PCR validation of the FGFR2 mutation from patient 253 showing results for plasma at day 1 
and EOT.  
EOT – end of treatment, HR – homologous recombination, MMR – mismatch repair, ctDNA – 
circulating tumor DNA 
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Figure 2. Genetic landscape of breast cancer driver genes in paired plasma samples on 
PALOMA-3 with frequent selection of mutations on treatment 
 A – Paired ctDNA sequencing results with frequency of observed variants in genes included in the 
targeted driver gene panel (SNVs and indels). Results are shown for both day 1 and end of treatment 
in 195 patients with matched data from day 1 and EOT. P values McNemar’s test with continuity 
correction. 
 B – RB1 mutations identified at EOT in patients treated with palbociclib plus fulvestrant (6/127). No 
RB1 mutations were identified in the EOT plasma samples from patients treated with placebo and 
fulvestrant (n = 68). The digital PCR plot shows orthogonal validation of Q257X in the EOT sample 
from patient 418. 
C – End of treatment (EOT) ctDNA sequencing results from 195 patients with paired samples, split by 
treatment, and whether the mutation status changed on treatment between day 1 and EOT. The 
cohort of 195 patients is formed from both the targeted sequencing cohort (n = 184) and exome 
sequencing cohort (n = 14, with n = 3 in both sets, see Supplementary figure 1). The pattern of 
mutation acquisition is similar across both treatment arms. 
SNV – single nucleotide variant, indel – insertion or deletion, EOT – end of treatment, ctDNA – 
circulating tumor DNA. Mixed – patients with different variants in the same gene at day 1 and EOT. 
 
Figure 3. Positive selection of ESR1 Y537S on fulvestrant based treatment 
A – Percentages of patients at baseline and end of treatment with specific ESR1 mutations observed 
in paired ctDNA sequencing data (n = 195, treatment groups combined). Data includes bothfulvestrant 
plus placebo and fulvestrant plus palbociclib groups together. P values calculated from McNemar’s 
test with continuity correction, and q value after Bonferroni correction for multiple comparisons. 
B – Validation of acquired ESR1 Y537S end of treatment mutations with digital PCR (17/17). Allele 
fraction is plotted for each technique. 
C – Concordance between sequencing and digital PCR for allele fraction in patients with an ESR1 
Y537S mutation in ctDNA sequencing at either day 1 or end of treatment. Blue - concordant calls 
present in both sequencing and digital PCR. Orange - present only in digital PCR.  
 ctDNA – circulating tumor DNA 
 
Figure 4. Clonal evolution of breast cancer driver genes through treatment 
A – Individual variants for each gene in the treatment groups combined (n=195), split by variants 
maintained between day 1 and end of treatment, lost over the course of treatment, or acquired during 
treatment. A number of patients had polyclonal variants in a single gene, particularly ESR1. The 
majority of TP53 acquired variations are accounted for by a single patient acquiring 8 separate new 
variants at EOT (see also Supplementary figure 9). 
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B – Cartoon with data from patient 237 illustrating subclonal selection on treatment. A clonal PIK3CA 
mutation and an ESR1-mutant sub clone are detectable at day 1. Over the course of treatment the 
ESR1-mutant subclone present at day 1 is lost, with acquisition of a new ERBB2-mutant sub clone.  
C – Sankey diagram to illustrate changes in individual PIK3CA mutations through treatment in both 
treatment groups combined. Polyclonal mutations from a single patient are displayed separately.  
Only two PIK3CA mutations detected at day 1 are undetectable at EOT, one from a patient with the 
other polyclonal mutation detected at EOT. 
D – Clonal state diagram to illustrate changes in PIK3CA polyclonality through treatment, with each 
individual patient represented once at day1 and EOT. Inner track demonstrates clonal states, 
representing different combinations of PIK3CA mutations indicated by segments of the circle. The 
middle tracks show individual mutations in the clonal states. The outer track shows the number of 
patients with that specific combination of mutations at day 1 (green bar) and end of treatment (purple 
bar). The central arrows show changes between day1 and EOT. The plot incorporates data from both 
treatment arms (n = 195). 
E – Sankey diagram to illustrate changes in individual ESR1 mutations through treatment in both 
treatment groups combined. 
F – Clonal state diagram to illustrate changes in ESR1 polyclonality through treatment, with each 
individual patient represented once at day1 and EOT, legend see D. 
EOT – end of treatment 
 
Figure 5. New driver mutations are selected late on treatment with palbociclib plus fulvestrant 
A – Swimmers plot of patients with paired sequencing data who received palbociclib plus fulvestrant 
(n = 127) comparing PFS between patients with any acquired driver mutation at end of treatment (n = 
35) versus patients that did not acquire a new driver mutation (n = 92). P value calculated using log 
rank. 
B – Genetic landscape of breast cancer progressing after palbociclib plus fulvestrant treatment. Each 
box shows the percentage of patients with a mutation identified at EOT (gray) and the subset of these 
patients who have newly acquired a mutation by EOT (yellow) for each gene. Patients with the same 
gene detected mutant and day 1 and EOT, but with a different pattern of mutations in the gene, are 
not counted as being acquired. 
PFS – progression free survival, HR – hazard ratio, CI – Confidence interval, EOT – end of treatment 
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Supplementary figure 1. CONSORT diagram showing availability of patient plasma samples, and subsequent sequencing analyses. Presented 
analyses are in red. Paired mutation analysis included data from the targeted panel genes found in the exome sequencing cohort. D1 – day 1, 
EOT – End of treatment, QC – Quality control, LOH – Loss of heterozygosity. *Note 3 patients underwent both paired exome sequencing and 
targeted sequencing. 
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Supplementary figure 2. Kaplan Meier curve showing progression free survival (PFS) curves 
for the subset of 195 patients with data from paired plasma samples at day 1 and end of 
treatment. HR – hazard ratio, CI – confidence interval, p value is log rank, PAL – Palbociclib, 
FUL – Fulvestrant, PCB - Placebo 
  
 
 
 
 
 
 
 
Supplementary figure 3. The genes and genomic regions of the purity panel. Blue – Reference genes. Red – Genes for assessment through 
normalized read count for loss or gain. Green – Genes to be assessed for loss through a combination of normalized read count and loss of 
heterozygosity, amplicons located such as to include single nucleotide polymorphisms with a population prevalence > 20%. Yellow – 
Chromosomal regions commonly lost in breast cancer to be assessed in the same manner as the genes in green. 
CNV reference Chr Amplicons CNV target Chr Amplicons SNP regions SNPs Prevalence (%) SNP genes Chr Amplicons
ADORA3 1 18 HER2 17q12 22 16q24.3 103 54 RB1 13 119
INSIG2 2 16 EGFR 7p11 18 17p12 102 49 CDKN2A 9 134
EFHB 3 17 FGFR1 8p11 19 8p23.2 97 48 PTEN 10 128
EIF4E 4 17 FGFR2 10q26 16 11q23.3 110 41 Total 381
SMAD5 5 19 PIK3CA 3q26 20 22q13.31 104 36
TERT 5 19 CDK4 12q14 21 1p36.13 106 29
TMEM248 7 17 CCND1 11q13 17 6q27 108 28
HNRPK 9 19 CCNE1 19q12 23 3p21.31 97 26
HOGA1 10 16 ESR1 6q25 22 Total 827
FOLH1 11 19 MYC 8q24 21
OR8S1 12 17 MCL1 1 16
ATP12A 13 20 Total 215
RPPH1 14 16
TTC5 14 18
ANXA2 15 19 Summary Amplicons
EFTUD2 17 19 CNV targets 11 215
AQP4-AS1 18 19 CNV reference 19 340
XRN2 20 16 SNP genes 3 381
SCAF4 21 19 SNP regions 8 827
Total 340 Total 1763
 Supplementary figure 4. Mutation burden in circulating tumour DNA at day 1 and end of 
treatments for patients with paired exome sequencing. D1 – day 1, EOT – End of treatment. 
 
 Supplementary figure 5. Percentage of metagenome affected by single copy gains/losses in 
patients with paired exome sequencing. D1 – day 1, EOT – End of treatment. 
 
 
 
 Supplementary figure 6. Clonal analysis of samples with paired exome sequencing data 
using PyClone. Lines show sub clonal fraction between baseline and end of treatment where 
separate clones have been identified. 
  
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary figure 7. CONSORT diagram for sequencing of plasma DNA samples to 
reduce PCR and sequencing error. A total of 585 samples went into the library preparation 
workflow for both a Proton and a KAPA library. This yielded 206 patients with libraries for 
both sequencing platforms at both day 1 and end of treatment. Each DNA sample underwent 
two separate library preparations for each time point, such that one could be sequenced on 
a HiSeq2500, and one on the Proton, with a cross-comparison made to remove PCR and 
sequencing error. Only time points with both libraries passing QC were sequenced. 
 
 Supplementary figure 8.  Allele fractions of emergent RB1 mutations in the 4/6 samples also 
with a PIK3CA mutation, the consistently lower allele fraction of the RB1 variants suggesting 
potentially sub clonal status. 
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Supplementary figure 9. Allele fractions of multiple detected TP53 variants in patient 
58 between day 1 and end of treatment. Amino acid codes correspond to transcript 
NM_000546. 
 
  
 
Supplementary figure 10. Validation of acquired mutation calls in PIK3CA from the paired 
ctDNA sequencing for H1047R, H1047L, E545K and E542K. 18 acquired mutations were 
identified in 17 patients from both treatment arms, one of these mutations in a patient who 
had a PIK3CA mutation at baseline and was found to have an additional one at the end of 
treatment. Of the 18 acquired mutations, 16 were H1047R, H1047L, E545K or E542K, all of 
these validating by ddPCR and showing close agreement with the sequencing allele fraction. 
  
Supplementary figure 11. Difference in prevalence between specific PIK3CA mutations at 
day 1 and end of treatment in both treatment arms (n = 195). There was a significant 
increase in E542K (p = 0.041, McNemar’s test with continuity correction) between day 1 and 
end of treatment, although this was not significant once a correction was made for multiple 
testing (q = 0.41, Bonferroni correction). 
 
  
Supplementary figure 12. Concordance between baseline assessment of PIK3CA mutation 
between targeted sequencing and digital PCR. Comparison made for the PIK3CA mutations 
E542K, E545K, H1047R, H1047L. Excludes exome sequencing data. The 6 data points 
shown in green demonstrate mutation calls only made in the digital PCR data, representing 
6/18 (33.3%) of mutations observed to be acquired in the paired sequencing. 
  
Supplementary figure 13. Percentage of patients acquiring a new mutation split between 
treatment arms. Upper panel – placebo + fulvestrant, lower panel – palbociclib +fulvestrant. 
  
Supplementary figure 14. Mutations called in each patient by treatment. Squares per gene are colour coded to show the fate on treatment of 
subclones where more than one variant was identified at a single time point. 
  
Supplementary figure 15. Concordance between baseline assessment of ESR1 mutation 
between targeted sequencing and digital PCR. Comparison made for the ESR1 mutations 
D538G, Y537S,Y537N, Y537C, L536R, S463P, E380Q. Excludes exome sequencing data.  
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Supplementary figure 16. Kaplan Meier curve comparing the progression free survival in 
days between patients with a Y537S mutation at the start of treatment and patients without a  
Y537S mutation at the start of treatment who went on to acquire one by the end of 
treatment.  
 Supplementary figure 17. Percentages of specific ESR1 mutations acquired in patients receiving palbociclib plus fulvestrant (n = 127) or 
placebo and fulvestrant (n = 68).  
 Supplementary figure 18. Copy number assessment comparison between day 1 and end of 
treatment (eot) from exome sequencing of plasma DNA for n = 14 patients receiving 
palbociclib plus fulvestrant showing stable copy number profiles adjusted for purity. 
  
Supplementary figure 19. Regions significantly deviated from baseline in copy number data from the paired plasma exome samples (n = 14) 
compared between baseline and end of treatment using GISTIC. 
  
Supplementary figure 20. Copy number assessment comparison of RB1 between day 1 and end of treatment (eot) from exome sequencing of 
plasma DNA for n = 14 patients receiving palbociclib plus fulvestrant. Differences seen in patients 152 and 392 are likely due to differentials in 
tumor purity between the time points (see Supplementary figure 17). 
 Supplementary figure 21. Number of patient samples at day 1 and end of treatment identified 
as having purity over 10% and over 20%, and overlap of assessable paired samples. EOT – 
End of treatment. 
 
 
Supplementary figure 22. Example copy number analysis from patient 269 day 1 
sample, top copy number LogR bottom B allele frequency. Homozygous loss of 
PTEN (exons 1-5) and RB1 (intronic). 
  
Supplementary figure 23. Heatmap shows copy number and purity assessments for all 
paired samples with purity > 20% at both time points, n = 17 pairs, separated by treatment n 
= 9 palbociclib plus fulvestrant and n = 8 placebo plus fulvestrant. Gray squares indicate 
where CCNE2 was not assessable see Materials and Methods. Data for paired samples with 
purity > 10% is shown in Supplementary figure 24.  
  
 
Supplementary figure 24. Bar charts show comparison of proportions of loss in RB1, PTEN and CDKN2A in unpaired day 1 (n = 37) and EOT 
(n = 51) samples with purity > 20% P values from Fisher’s exact test. EOT – end of treatment. Loss of PTEN was observed in similar 
proportions of day 1 and end of treatment samples (4/37, 10.8% versus 8/51, 15.7%, p = 0.75 Fisher’s exact test), similarly to loss of CDKN2A 
(day 1 8/37, 21.6%, end of treatment   9/51, 17.6%, p = 0.79, Fisher’s exact test). 
Supplementary figure 25. Comparison of copy number status in patients with paired day 1 and end of treatment (eot) samples with at least 10% 
tumor purity at both day 1 and end of treatment (n = 43 pairs). Gray squares in the lower panel indicate samples where CCNE2 was not 
assessable. There was no difference in rates of loss of RB1, PTEN or CDKN2A between day 1 and end of treatment in the larger subset of 
samples of >10% tumor purity shown here.
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Supplementary figure 26. Swimmer plots of progression free survival in the placebo and 
fulvestrant arm comparing patients with (upper panel) and without (lower panel) newly 
acquired or selected mutations at the end of treatment. PFS – progression free survival, p 
value log rank. 
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Supplementary figure 27. Kaplan Meier curves comparing progression free survival in the 
palbociclib plus fulvestrant arm between patients who acquired or selected at least 1 
mutation and those who did not. PFS – progression free survival, CI – confidence interval. 
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Supplementary figure 28. Kaplan Meier curves comparing progression free survival in the 
placebo plus fulvestrant arm between patients who acquired or selected at least 1 mutation 
and those who did not. PFS – progression free survival, CI – confidence interval. 
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Supplementary figure 29. Kaplan Meier curves comparing progression free survival in the 
palbociclib plus fulvestrant arm between patients who acquired or selected an ESR1 
mutation and those who did not. PFS – progression free survival, NE – not estimable, CI – 
confidence interval. 
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Supplementary figure 30. Kaplan Meier curves comparing progression free survival in the 
palbociclib plus fulvestrant arm between patients who acquired or selected a PIK3CA 
mutation and those who did not. PFS – progression free survival, NE – not estimable, CI – 
confidence interval. 
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Supplementary figure 31. Kaplan Meier curve of progression free survival in the palbociclib 
plus fulvestrant arm comparing patients with acquired RB1 mutation (n = 6) to those without 
(n = 121). 
  
 
Supplementary figure 32. Observed variation in allele frequency around germline SNPs in 
buffy coat samples run for purity panel validation at different coverage intervals. 
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Supplementary figure 33. Validation of purity panel purity estimate against CLONET.  
Spearman’s r = 0.92 
p = 0.0006 
  
 
Supplementary figure 34. Observed prevalence of loss regions in purity validation set 
compared to prevalence in The Cancer Genome Atlas. 
 
0
10
20
30
40
50
60
11q23.3 16q24.3 17p12 1p36.13 22q13.31 3p21.31 6q27 8p23.2
% Observed
TCGA prevalence
  
Supplementary figure 35. Validation of sequencing approach (see Materials and Methods). A 
control blend of plasma DNA with dilutions of known concentration of circulating tumor DNA 
was used with an amplicon-based panel and sequenced to 2000X. The Venn diagram red 
circles illustrate the calls made with the standard Ampliseq library preparation, the green 
circles those with libraries completed with the KAPA hyper prep kit to demonstrate accurate 
error removal with cross comparison of calls. The two green circles are the same libraries 
sequenced twice. Calls made with a threshold of 0.5% with pileup and iDES (see Materials 
and Methods) with minimum coverage of 50 and minimum alternative reads of 5. The extra 
calls beyond the two controls in the high purity positive control (AX) are additional subclonal 
ESR1 and TP53 mutations. 
 Supplementary tables 
 
 
 
 
 
 
 
 
Supplementary table 1. Sample details for patients who underwent exome sequencing of paired day 1 and end of treatment samples. Samples 
of sufficient purity (>10% in all but one case of 8%) were identified through either digital PCR for PIK3CA or ESR1 mutations, or with targeted 
sequencing of SNPs using the purity panel. 
Lab ID Screen
PIK3CA  mut 
1
PIK3CA  mut 
2
Estimated 
total D1 AF
ESR1  mut 1 ESR1  mut 2 ESR1  mut 3 ESR1  mut 4 ESR1  mut 5
ESR1  total 
AF
EOT mut 
tested
Estimated 
total EOT AF
Days on 
treatment
Matched 
buffy
34 ddPCR E545K E542K 0.16 0 0 0 0 0 0.00 E545K 0.14 226
79 ddPCR H1047R 0 0.30 D538G Y537N 0 0 0 0.25 H1047R 0.19 59 TRUE
80 ddPCR E545K 0 0.28 0 0 0 0 0 0.00 E545K 0.32 63
82 ddPCR H1047R 0 0.19 D538G Y537N 0 0 0 0.02 H1047R 0.35 48
152 ddPCR H1047R 0 0.35 D538G Y537N Y537S E380Q S463P 0.05 H1047R 0.18 68
253 ddPCR H1047R 0 0.17 D538G E380Q 0 0 0 0.04 H1047R 0.32 53 TRUE
392 ddPCR 0 0 0.00 D538G E380Q 0 0 0 0.17 D538G 0.08 182
333 ddPCR H1047R 0 0.40 Y537S 0 0 0 0 0.03 H1047R 0.53 634 TRUE
390 ddPCR E545K 0 0.43 0 0 0 0 0 0.00 E545K 0.59 233
187 ddPCR E545K 0 0.08 0 0 0 0 0 0.00 E545K 0.10 56
61 LOH 0 0 0.23 0 0 0 0 0 0.00 LOH 0.23 57 TRUE
182 LOH 0 0 0.13 0 0 0 0 0 0.00 LOH 0.12 53
293 LOH 0 0 0.29 0 0 0 0 0 0.00 LOH 0.27 287 TRUE
387 LOH 0 0 0.26 0 0 0 0 0 0.00 LOH 0.19 169
404 LOH 0 0 0.22 0 0 0 0 0 0.00 LOH 0.27 168
422 LOH 0 0 0.18 0 0 0 0 0 0.00 LOH 0.72 171
Day 1 (D1) End of treatment
 Supplementary table 2. Coverage and duplicates data for samples having undergone paired 
exome sequencing. Day 1 – Day 1 sample. EOT – End of treatment sample. BC – Buffy coat 
sample. 
Sample Material Median Duplicates On target
34 day 1 Plasma 134 41% 75%
34 EOT Plasma 140 34% 76%
79 day 1 Plasma 116 20% 72%
79 EOT Plasma 122 18% 77%
80 day 1 Plasma 100 24% 75%
80 EOT Plasma 119 23% 76%
82 day 1 Plasma 91 35% 72%
82 EOT Plasma 112 22% 76%
152 day 1 Plasma 38 68% 61%
152 EOT Plasma 121 26% 75%
253 day 1 Plasma 104 27% 72%
253 EOT Plasma 105 28% 72%
392 day 1 Plasma 145 41% 72%
392 EOT Plasma 167 26% 75%
61 day 1 Plasma 179 22% 74%
61 EOT Plasma 166 26% 69%
182 day 1 Plasma 162 25% 73%
182 EOT Plasma 178 24% 72%
187 day 1 Plasma 139 28% 69%
187 EOT Plasma 150 34% 65%
293 day 1 Plasma 172 18% 74%
293 EOT Plasma 196 16% 77%
333 day 1 Plasma 178 14% 76%
333 EOT Plasma 200 14% 77%
387 day 1 Plasma 195 15% 77%
387 EOT Plasma 173 12% 77%
390 day 1 Plasma 181 17% 77%
390 EOT Plasma 175 12% 75%
404 day 1 Plasma 212 15% 77%
404 EOT Plasma 193 14% 75%
422 day 1 Plasma 179 17% 70%
422 EOT Plasma 187 11% 73%
79BC Buffy 58 22% 76%
253BC Buffy 58 23% 76%
61BC Buffy 49 6% 75%
293BC Buffy 47 6% 76%
333BC Buffy 47 6% 80%
108BC Buffy 45 6% 77%
6BC Buffy 47 6% 76%
207BC Buffy 34 51% 72%
207T Tumor 66 40% 77%
 Supplementary table 3. Mutational signature analysis of exome sequencing variants. Day 1– Day 1 sample. EOT – End of treatment sample.  
 
 
Patient Signature.1 Signature.2 Signature.3 Signature.5 Signature.6 Signature.7 Signature.9 Signature.10 Signature.12 Signature.13 Signature.15 Signature.16 Signature.20 Signature.21 Signature.24 Signature.26 Signature.30
152 day 1 0.6391079 0 0.1685734 0 0 0 0 0 0 0 0 0 0 0.074844318 0 0 0
152 EOT 0.5418774 0 0.1545973 0 0 0 0 0 0 0 0.13740699 0.06651358 0 0 0 0 0
182 day 1 0.7945949 0 0 0 0.0991347 0 0 0.06608758 0 0 0 0 0 0 0 0 0
182 EOT 0.8661228 0 0.0892266 0 0 0 0 0 0 0 0 0 0 0 0 0 0
187 day 1 0.425692 0 0 0.3333117 0 0 0 0 0 0 0 0 0 0 0.1888072 0 0
187 EOT 0.2889863 0 0 0 0 0 0 0 0 0.17673132 0 0.11400976 0.22230187 0 0 0 0.19797078
253 day 1 0.5967391 0.0762137 0.1893982 0 0 0 0 0 0 0 0 0 0 0 0 0.07945898 0
253 EOT 0.7319089 0.2046768 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
293 day 1 0.8490427 0 0 0 0 0 0.1011275 0 0 0 0 0 0 0 0 0 0
293 EOT 0.8013355 0 0 0 0 0 0.1585412 0 0 0 0 0 0 0 0 0 0
333 day 1 0.373423 0 0 0 0.2408562 0 0.2958088 0 0 0 0 0 0 0 0 0 0
333 EOT 0.6062531 0 0 0 0.0737334 0 0.2942255 0 0 0 0 0 0 0 0 0 0
34 day 1 0.6873836 0.0764492 0 0 0 0 0 0 0.15404952 0 0 0 0 0 0 0 0
34 EOT 0.8836091 0.0684726 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
387 day 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
387 EOT 0.9758265 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
390 day 1 0.6566263 0.0769042 0 0 0 0.0820245 0 0.11327968 0 0.07116539 0 0 0 0 0 0 0
390 EOT 0.4936215 0.1781913 0 0 0 0.100286 0 0.12069709 0 0.09402304 0 0 0 0 0 0 0
392 day 1 0.5231784 0.1714332 0 0 0 0 0 0.13100183 0 0 0 0 0 0.075328039 0 0 0
392 EOT 0.792347 0.0769466 0 0 0 0 0 0.12534358 0 0 0 0 0 0 0 0 0
404 day 1 0.914459 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
404 EOT 0.9203781 0 0 0 0 0.0796219 0 0 0 0 0 0 0 0 0 0 0
422 day 1 0.8835858 0 0 0 0 0 0 0 0 0 0 0.11641421 0 0 0 0 0
422 EOT 0.8014821 0 0 0 0 0 0 0 0 0 0.159884 0 0 0 0 0 0
61 day 1 0.1888024 0 0.5091002 0 0 0 0.0621701 0 0 0 0.08239073 0 0 0 0 0 0
61 EOT 0.1828287 0 0.5292476 0 0 0 0 0 0 0.09921806 0 0 0 0 0 0 0
79 day 1 0.8357276 0 0 0 0 0.0870947 0.0627623 0 0 0 0 0 0 0 0 0 0
79 EOT 0.7627272 0 0 0 0 0.0787664 0.1313305 0 0 0 0 0 0 0 0 0 0
80 day 1 0.8012931 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.09725907 0
80 EOT 0.792105 0 0.0634433 0 0 0 0 0 0 0 0 0 0 0 0 0 0
82 day 1 0.6188254 0 0 0 0 0 0 0 0 0.13249308 0.11572246 0 0 0 0 0 0
82 EOT 0.6970892 0 0 0 0 0 0 0 0 0.09628119 0 0 0 0 0 0.13475991 0
  
 
 
 
 
 
 
Supplementary table 4. Genetic aberrations in immune signalling, NF1 and NOTCH pathway genes from exome sequencing. D1 – Day 1. EOT 
– End of treatment. Chr – Chromosome. Patient 61 had newly emergent mutations in FBXO40 and LTN1, both E3 ubiquitin ligases associated 
with regulation of class I MHC antigen processing and presentation. Patients 333 and 390 featured emergent mutations in TMEM173 and 
MEFV respectively, the former a promotor of interferons alpha and beta and the latter regulating the response to interferon gamma, both 
processes potentially relevant to the immune-mediated effects of palbociclib (16, 17) . 4/14 (28.6%) of patients with samples analyzed had an 
aberration in NOTCH family receptors and 2/14 (14.3%) mutations in NF1 
Patient Chr Position Reference Alternative Change Gene Function D1 AF EOT AF
61 3 121345699 C A nonsynonymous_SNV FBXO40 Substrate-determining subunit of E3 ubiquitin ligase 0 0.105
61 21 30331933 C T nonsynonymous_SNV LTN1 Listerin E3 Ubiquitin Protein Ligase 0 0.078125
253 1 158324190 C T nonsynonymous_SNV CD1E Required for the presentation of glycolipid antigens 0 0.235955
333 5 138860775 G A nonsynonymous_SNV TMEM173 Promotes the production of type I interferon (IFN-alpha and IFN-beta) 0 0.045802
390 16 3293474 C G nonsynonymous_SNV MEFV Regulates inflammatory response in response to IFNG/IFN-gamma 0 0.029891
182 1 120458435 TG T frameshift_deletion NOTCH2 NOTCH receptor 0.169399 0.192118
390 19 15292441 G A nonsynonymous_SNV NOTCH3 NOTCH receptor 0.591954 0.491124
80 6 32168958 AGGTGG A frameshift_deletion NOTCH4 NOTCH receptor 0.273973 0.424837
61 1 120458305 C A nonsynonymous_SNV NOTCH2 NOTCH receptor 0.037736 0
82 17 29585383 C T stopgain NF1 NF1 0.247059 0.547297
61 17 29663382 G C nonsynonymous_SNV NF1 NF1 0.205556 0.29932
Immune 
pathway
NOTCH 
family 
receptors
NF1
    Day 1 (n) End of treatment (n) Paired (n) 
Fisher's p 
Unpaired 
analysis 
McNemar's p 
Paired 
analysis 
>10% 
tumor 
purity 
RB1 68 82 43 0.1 0.72 
PTEN 68 82 43 0.55 1 
CDKN2A 68 82 43 0.62 0.22 
>20% 
tumor 
purity 
RB1 37 51 17 0.3 0.25 
PTEN 37 51 17 0.75 NA 
CDKN2A 37 51 17 0.79 0.48 
 
Supplementary table 5. Comparative statistical analyses conducted on the copy number data within samples falling into the >10% tumor purity 
and >20% tumor purity category. NA – unable to calculate p value. 
 
 
 Mutation 
acquired 
n = 53 
No 
mutation 
acquired 
n = 142 
p value 
Hormone receptor status, n(%)* n = 179   p = 0.52 
ER-/PR- 
16 (30.2) 32 (22.5) 
 
ER-/PR+ 0 (0) 3 (2.1)  
ER+/PR- 14 (26.4) 37 (26.1)  
ER+/PR+ 19 (35.8) 58 (40.8)  
Disease free interval ** n = 136   p = 0.61 
≤24 months 
6 (11.3) 21 (14.8) 
 
>24 months 32 (60.4) 77 (54.2)  
Menopausal status, n(%) n = 195   p = 0.80 
Pre/perimenopausal 
10 (18.9) 31 (21.8) 
 
Post-menopausal 43 (81.1) 111 (78.2)  
Sensitivity to prior endocrine treatment, n(%)   p = 1 
Yes 
41 (77.4) 109 (76.8) 
 
No 12 (22.6) 33 (23.2)  
Visceral metastases, n(%)   p = 1 
Yes 
33 (62.3) 89 (62.7) 
 
No 20 (37.7) 53 (37.3)  
Bone metastases, n(%)   p = 0.013 
(q = 0.15) 
Yes 
48 (90.6) 103 (72.3) 
 
No 5 (9.4) 39 (27.5)  
Soft tissue/nodal metastases, n(%)   p = 0.89 
Yes 
20 (37.7) 57 (40.1) 
 
No 33 (62.3) 85 (59.9)  
Prior endocrine therapies, n(%)   p = 0.91 
Tamoxifen only 
7 (13.2) 17 (12.0) 
 
AI only 25 (47.2) 64 (45.1)  
AI and tamoxifen 21 (39.6) 61 (43.0)  
Prior chemotherapy, n(%)   p = 0.56 
Neoadjuvant/adjuvant 
22 (41.5) 56 (39.4) 
 
Metastatic +/- adjuvant 21 (39.6) 49 (34.5)  
None 10 (18.9) 37 (26.1)  
Prior lines of therapy for metastatic disease, 
n(%) 
  p = 0.16 
0 
10 (18.9) 28 (19.7) 
 
1 27 (50.9) 53 (37.3)  
2 15 (28.3) 48 (33.8)  
3+ 1 (1.9) 13 (9.2)  
Number of disease sites, n(%)   p = 0.80 
1 
17 (32.1) 47 (33.1) 
 
2 13 (24.5) 37 (26.1)  
3+ 23 (43.4) 58 (40.8)  
    
 
 Supplementary table 6. Comparison of baseline clinic-pathological characteristics between 
patients who acquire a mutation on treatment and those who do not. P values are from Chi-
squared except for ordinal variables where the Cochran-Armitage test is used. The corrected 
p value for the association with bone metastases is q = 0.15 (Bonferroni). 
* 16 instances of ‘not specified’ were removed for the analysis. 
** 59 instances of ‘not applicable’ were removed for the analysis 
 
 
  
 
 
 
 
 
 
 
Supplementary table 7. Validation of loss of heterozygosity method for estimating tumor content of plasma samples. Samples with known 
mutation allele fractions detected by digital PCR were compared to purity estimates made on sequencing data from the purity panel using 
CLONET and the loss of heterozygosity purity estimate. 
 
Sample Type Aberration Frequency ddPCR Purity sequencing mut Global purity CLONET Local purity CLONET Single sample
17T Tumour FGFR1  amp - None identified no estimate no estimate 75.0%
21P Plasma FGFR2  amp - None identified no estimate no estimate 49.0%
207T Tumour FGFR1  amp - None identified no estimate no estimate 76.0%
269P Plasma FGFR2  amp - None identified no estimate no estimate no estimate
316T Tumour FGFR2  amp - None identified 43.0% 43.0% 46.0%
Sample Type Aberration Frequency ddPCR Purity sequencing Global purity CLONET Local purity CLONET Single sample
1135 Plasma None known - None identified no estimate no estimate no estimate
2039 Plasma None known - None identified no estimate no estimate no estimate
1037 Plasma None known - None identified no estimate no estimate no estimate
1156 S Plasma PIK3CA 0.005 Not called no estimate 11.5% 16.0%
1117 S Plasma PIK3CA 0.026 Not called no estimate no estimate no estimate
1144 S Plasma ESR1 0.327 or 0.019 Not called no estimate 29.9% 20.0%
1150 E Plasma PIK3CA 0.037 0.034 no estimate no estimate no estimate
1025 S Plasma PIK3CA/ESR1 0.09 PIK3CA 0.073,  ESR1 0.056 no estimate 23.6% 19.0%
1086A ex1 Plasma PIK3CA 0.13 0.11 no estimate 3.0% 11.0%
1153 S Plasma PIK3CA 0.171 0.143 no estimate 3.0% 10.0%
1158 S Plasma PIK3CA 0.094 0.152 no estimate 11.3% 21.0%
1016 E Plasma ESR1 0.192 0.226 40.0% 35.3% 28.0%
1118B ex1 Plasma PIK3CA 0.24 0.23 44.0% 53.7% 41.0%
1147 E Plasma TP53 0.76 Not in panel 70.0% 83.3% 71.0%
1126 S Plasma PIK3CA 0.839 0.824 70.0% 82.6% 72.0%
  
 
 
 
 
 
 
 
 
 
Supplementary table 8. Variation in allele fraction estimate for known heterozygous single 
nucleotide polymorphisms (SNPs) in the germline samples used in the purity panel validation 
run. 
